发明名称 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION
摘要 The use of a compound of formula (1): wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s) of the substituent groups R1 to R6 may together form a 3, 4, 5, 6, 7 or 8-membered ring containing 0, 1 or 2 heteroatom(s); R7 is selected from alkyl, aryl and non-aromatic heterocyclic groups, and R8 is selected from hydrogen, halogen, alkyl, aryl and non-aromatic heterocyclic groups; and pharmaceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission; novel compounds of formula (1) <i>per se</i> and for use in therapy.
申请公布号 WO0208219(A3) 申请公布日期 2002.06.13
申请号 WO2001GB03321 申请日期 2001.07.25
申请人 VERNALIS RESEARCH LIMITED;SNAPE, MICHAEL, FREDERICK;GILLESPIE, ROGER, JOHN;DAWSON, CLAIRE, ELIZABETH;MCATEER, STEVEN, MICHAEL;GAUR, SUNEEL 发明人 SNAPE, MICHAEL, FREDERICK;GILLESPIE, ROGER, JOHN;DAWSON, CLAIRE, ELIZABETH;MCATEER, STEVEN, MICHAEL;GAUR, SUNEEL
分类号 A61K31/13;A61K31/137;A61K31/381;A61K31/4025;A61K31/4436;A61K31/4535;A61K31/5377;A61P3/10;A61P7/04;A61P9/02;A61P9/10;A61P25/00;A61P25/02;A61P25/04;A61P25/06;A61P25/08;A61P25/14;A61P25/16;A61P25/18;A61P25/20;A61P25/22;A61P25/24;A61P25/28;A61P25/30;A61P27/02;A61P27/06;A61P29/00;A61P31/18;A61P35/00;A61P43/00;C07C211/19;C07C211/27;C07C217/56;C07C217/74;C07D333/20 主分类号 A61K31/13
代理机构 代理人
主权项
地址